EC Number   |
General Information |
Reference |
|---|
    1.1.1.95 | drug target |
high expression of the enzyme (PHGDH) is dramatically related to tumor resistance to chemotherapies, and treatment with PHGDH inhibitor works synergistically with chemotherapy drugs and may be an effective approach to improve overall patient survival |
763147 |
| 1.1.1.95 | drug target |
potential cancer therapy target |
763090 |
| 1.1.1.95 | drug target |
since the enzyme controls flux through the sreine biosynthetic pathway it represents a putative target in oncology |
762795 |
| 1.1.1.95 | drug target |
the enzyme is an attractive drug target in tumors that overexpress PHGDH or amplify the PHGDH gene |
763347 |
| 1.1.1.95 | malfunction |
3-PGDH deficiency is a rare recessive inborn error in the biosynthesis of the amino acid L-serine characterized clinically by congenital microcephaly, psychomotor retardation, and intractable seizures. The biochemical abnormalities associated with this disorder are low concentrations of L-serine, D-serine, and glycine in cerebrospinal fluid |
698189 |
| 1.1.1.95 | malfunction |
enzyme-depleted astrocytes accumulate 20fold less L-serine compared with controls |
738901 |
| 1.1.1.95 | malfunction |
lacking of isoform EDA9 expression causes drastic developmental defects |
739373 |
| 1.1.1.95 | malfunction |
mutations in the human PHGDH cause serine deficiency disorders characterized by severe neurological symptoms including congenital microcephaly and psychomotor retardation, growth retardation phenotypes seen in human patients suffering from SDD caused by PHGDH mutations, overview |
698067 |
| 1.1.1.95 | malfunction |
PGDH deficiency results in metabolic defects of the nervous system whose systems range from microcephaly at birth, seizures, and psychomotor retardation |
763090 |
| 1.1.1.95 | malfunction |
PGDH1-silenced lines are inhibited in growth |
739293 |
